UHS' 21% YTD slide has cheapened its valuation, but weaker volumes, ACA pressure and lower growth forecasts keep risks elevated.

According to the average brokerage recommendation (ABR), one should invest in Tenet (THC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Universal Health's $835M Talkspace acquisition expands virtual behavioral health, adding 6,000 providers and new growth opportunities.

Five top-ranked stocks, including Centene and Fortinet, stand out for strong earnings-surprise histories that could support future beats.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

CYH trades at a deep discount to peers as acquisitions, cost control and debt reduction progress, but cash flow remains a concern.

THC's hospital growth is fueling earnings momentum as stronger volumes, revenues and margins help offset exchange weakness.

Top-ranked stocks CNC, THC, FTNT, U and GS are likely to beat on the bottom line in their upcoming releases.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 26.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

ACHC's premium valuation faces a key test as facility growth and stronger EBITDA guidance compete with rising costs and weaker returns.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Technical signal puts fresh focus on Tenet Healthcare stock Tenet Healthcare (THC) recently triggered a golden cross, as its 50 day simple moving average moved above the 200 day level. The stock has also recorded gains over the past month. See our latest analysis for Tenet Healthcare. The recent golden cross comes on top of a strong run for Tenet Healthcare, with a 30 day share price return of 36.95% and a year to date share price return of 33.76%. Over longer horizons, total shareholder...

Recently, Tenet Healthcare reported a bullish technical “golden cross” alongside higher earnings estimates, while management raised its 2026 adjusted EPS guidance and outlined further investment in its ambulatory care platform. The company’s emphasis on higher-acuity services, expanding outpatient capabilities, and strengthened earnings outlook has reinforced investor attention on its evolving business mix and growth priorities. Against this backdrop, we’ll explore how Tenet Healthcare’s...

ROKU, THC and CZFS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 12, 2026.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

CNR, IX, THC, SOLS and KMX have been added to the Zacks Rank #1 (Strong Buy) List on August 12, 2026.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Tenet Healthcare Corporation (NYSE:THC) has quietly become one of the strongest-performing healthcare stocks in the market, surging more than 270% over the past five years. That rally reflects a business that has changed significantly: Tenet (NYSE:THC) has expanded its ambulatory surgery platform, increased its focus on higher-acuity care, and materially improved cash generation. The latest […]

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Tenet (THC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Tenet Healthcare has delivered a very strong 270.6% return over the past 5 years, so the key issue for investors now is whether the current price still lines up with what the valuation checks suggest about the stock. The 270.6% 5 year return highlights how much expectations have shifted and raises the bar for any further gains to be supported by fundamentals. Recent optimism around revenue growth and margin execution can support the current valuation, while any setback in managing costs or...

EHC's higher occupancy, rising discharges and hospital expansion could support Q2 growth, but can they offset mounting operating costs?

Top-ranked stocks EL, BCC, THC, SIMO and VLO are likely to beat on the bottom line in their upcoming releases.

Tenet Healthcare’s second quarter was marked by robust operational execution, with management attributing outperformance to growth in higher-acuity care, disciplined expense controls, and technology-enabled cost management programs. CEO Saum Sutaria emphasized the company’s focus on targeted service line expansion and efficiency initiatives. These efforts enabled Tenet to navigate payer mix shifts and exchange enrollment declines, with management highlighting strong commercial and Medicaid reven

Millions of Americans dropped their Affordable Care Act plans when subsidies expired and now struggle to pay.

Ensign Group beats Q2 earnings and raises its 2026 outlook as higher occupancy, patient days and acquired facilities drive revenue growth.

Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Tenet (THC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Does Tenet Healthcare (THC) have what it takes to be a top stock pick for momentum investors? Let's find out.

HUM's Q2 earnings top estimates as medical membership growth, premium gains and CenterWell strength lift results despite higher costs.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ACHC beats Q2 earnings and revenue estimates as admissions rise and residential treatment grow, prompting higher 2026 guidance despite profit pressure.

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.

UHS tops Q2 earnings and revenue estimates as Acute Care and Behavioral Health growth lifts results, even as higher costs weigh on operations.

Bank of America's trading, investment banking and digital expansion drive growth, but rising costs and market volatility pose key challenges.

THC raised its 2026 outlook after Q2 earnings and revenues beat expectations, driven by strong same-facility growth and disciplined expense management.

Tenet Healthcare (THC) is demonstrating improved operational execution as cost discipline across its

The hospital operator recorded a $65 million hit from turbulence on the Affordable Care Act exchanges in the second quarter, but avoided the worse repercussions slamming some of its peers.

The Morning Bull - US Market Morning Update Monday, Jul, 27 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up 0.03%, as investors weigh signs of steady US growth against lingering inflation and interest rate questions. New single family home sales reached a 628,000 annual pace in June, up 1.6% for the first monthly rise in three months, which hints that housing is holding up even with higher borrowing costs. At the same time, the US Services PMI...

Moby summary of Tenet Healthcare Corporation's Q2 2026 earnings call

Tenet Healthcare reported past second-quarter 2026 results showing revenue of US$5,628 million and net income of US$826 million, with basic earnings per share from continuing operations rising to US$9.89 from US$3.16 a year earlier. Alongside these results, the company lifted its full-year 2026 outlook for revenue, net income, and earnings per share while expanding its share repurchase program by US$2 billion. We will now examine how Tenet Healthcare’s stronger full-year 2026 guidance and...

Higher-acuity shift drives guidance hikes across revenue and cash flow.

Tenet Healthcare Corp (THC) reports robust financial performance with significant EBITDA growth and increased guidance for 2026.

Shares of hospital operator Tenet Healthcare (NYSE:THC) jumped 23.5% in the morning session after the company reported second-quarter 2026 results that exceeded analyst expectations and substantially raised its full-year guidance. Tenet posted adjusted earnings per share of $6.12, easily beating the consensus estimate of $4.26. Quarterly revenue also surpassed forecasts, coming in at $5.63 billion compared to the anticipated $5.42 billion. Following the strong performance, the company lifted its

Oil prices continued to retreat on reports that Pakistan, with support from China, was seeking to revive negotiations between the U.S. and Iran.

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S